NASDAQ:GRPH
Graphite Bio, Inc.
- Stock
locale
United Statesmarket
STOCKSindustry
Biotechnologywebsite
www.graphitebio.comipo date
Jun 25, 2021
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of...Show More
Earnings
Earnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus